1. In the first year of life, i.e., younger than 12 months at the start of the RSV season or born during the RSV season:
a. Infants born before 29 weeks, 0 days gestation;
b. Preterm infants with CLD of prematurity, defined as birth at less than 32 weeks, 0 days gestation and a requirement for more than 21% oxygen for at least the first 28 days after birth;
c. Certain infants with hemodynamically significant heart disease (e.g.. infants with acyanotic heart disease who are receiving medication to control congestive heart failure and will require cardiac surgical procedures; infants with moderate to severe pulmonary hypertension; infants with lesions adequately corrected by surgery who continue to require medication for heart failure;
i. Decisions regarding palivizumab prophylaxis for infants with cyanotic heart defects in the first year of life may be made in consultation with a pediatric cardiologist.
d. Children with pulmonary abnormality or neuromuscular disease that impairs the ability to clear secretions from the upper airways (e.g., ineffective cough, recurrent gastroesophageal tract reflux, pulmonary malformations, tracheoesophageal fistula, upper airway conditions, or conditions requiring tracheostomy); e. Children with cystic fibrosis who have at least one of the following conditions:
i. Clinical evidence of CLD; and/or ii. Nutritional compromise.
2. In the second year of life, i.e., younger than 24 months at the start of the RSV season:
a. Children who were born at less than 32 weeks, 0 days gestation and required at least 28 days of supplemental oxygen after birth and who continue to require medical intervention (supplemental oxygen, chronic corticosteroid, or diuretic therapy) during the 6-month period before the start of the second RSV season.
b. Children with cystic fibrosis who have either:
i. Manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable); or Respiratory Syncytial Virus Prophylaxis ii. Weight for length less than the 10 th percentile.
3. In the first or second year of life: a. Children who will be profoundly immunocompromised (e.g., will undergo solid organ or hematopoietic stem-cell transplantation or receive chemotherapy) during the RSV season.
4.
After surgical procedures that use cardiopulmonary bypass, for children who still require prophylaxis, a postoperative dose of palivizumab may be considered medically necessary after cardiac bypass or at the conclusion of extracorporeal membrane oxygenation for infants and children younger than 24 months.
When RSV Prophylaxis is not covered
Immunoprophylaxis for RSV is considered not medically necessary for:
• Infants and children with hemodynamically insignificant heart disease (e.g., secundum atria septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus); or • Infants with lesions adequately corrected by surgery, unless they continue to require medication for heart failure; or • Infants with mild cardiomyopathy who are not receiving medical therapy for the condition; or • Children with congenital heart disease in the second year of life.
Other indications for immune prophylaxis for RSV are considered investigational including, but not limited to, controlling outbreaks of health care-associated disease; or use in children with cystic fibrosis or Down syndrome without other risk factors; or in children over 2 years of age, unless criteria for medical necessity (outlined above) are satisfied.
Policy Guidelines

Dosing and Administration
Palivizumab is administered by intramuscular injection in a dose of 15 mg/kg of body weight per month. The anterolateral aspect of the thigh is the preferred injection site. Routine use of the gluteal muscle for the injection can cause sciatic nerve damage.
Clinicians may administer up to a maximum of 5 monthly doses of palivizumab (15 mg/kg per dose) during the RSV season to infants who qualify for prophylaxis. Qualifying infants born during the RSV season will require fewer doses. For example, infants born in January would receive their last dose in March.
Hospitalized infants who qualify for prophylaxis during the RSV season should receive the first dose of palivizumab 48 to 72 hours before discharge or promptly after discharge.
Breakthrough RSV
If any infant or young child receiving monthly palivizumab prophylaxis experiences a breakthrough RSV hospitalization, monthly prophylaxis should be discontinued because of the extremely low likelihood of a second RSV hospitalization in the same season (<0.5%).
Prevention of Health Care Associated RSV Disease
RSV is known to be transmitted in the hospital setting and to cause serious disease in high-risk infants. Among hospitalized infants, the major means to reduce RSV transmission is strict observance of infection control practices, including restriction of visitors to the neonatal intensive care unit during respiratory virus season and prompt initiation of precautions for RSV-infected infants. If an RSV outbreak occurs in a highrisk unit (e.g., pediatric or neonatal intensive care unit or stem cell transplantation unit), primary emphasis should be placed on proper infection control practices, especially hand hygiene. No data exist to support palivizumab use in controlling outbreaks of health care-associated disease, and palivizumab use is not recommended for this purpose.
Interactions
Palivizumab does not interfere with response to other scheduled childhood vaccines.
Palivizumab may interfere with RSV diagnostic tests that are immunologically-based (e.g., some antigen detection-based assays).
Risk Minimization Techniques
Infants, especially high-risk infants, never should be exposed to tobacco smoke. In published studies, passive household exposure to tobacco smoke has not been associated with an increased risk of RSV hospitalization on a consistent basis. However, exposure to tobacco smoke is a known risk factor for many adverse healthrelated outcomes. Exposure to tobacco smoke can be controlled by the family of an infant at increased risk of RSV disease, and preventive measures will be less costly than palivizumab prophylaxis.
For all infants, particularly those who are preterm, the environment should be optimized to prevent RSV and other viral respiratory infections by offering breast milk feeds, immunizing household contacts with influenza vaccine, practicing hand and cough hygiene, and by avoiding tobacco or other smoke exposure, and by not attending large group child care during the first winter season, whenever possible.
The policy statements are in agreement with the 2014 American Academy of Pediatrics (AAP) Guidelines.
Initiation and Termination of Immunoprophylaxis
Initiation of immunoprophylaxis in November and continuation for a total of 5 monthly doses will provide protection into April and is recommended for most areas of the United States. If prophylaxis is initiated in October, the fifth and final dose should be administered in February.
In the temperate climates of North America, peak RSV activity typically occurs between November and March, whereas in equatorial countries, RSV seasonality patterns vary and may occur throughout the year. The annual occurrence of the RSV season is predictable, but the severity of the season, the time of onset, the peak of activity, and the end of the season cannot be predicted precisely. Substantial variation in timing of community outbreaks of RSV disease from year to year exists in the same community and between communities in the same year, even in the same region. These variations occur within the overall pattern of RSV outbreaks, usually beginning in November or December, peaking in January or February, and ending by the end of March or sometime in April. Communities in the southern United States, particularly in Florida, tend to experience the earliest onset of RSV activity. In recent years, the national duration of the RSV season has been 21 weeks. Please note that the latest information regarding geographic seasonal variation can be found on the CDC website at http://www.cdc.gov/rsv/index.html .
Results from clinical trials indicate that palivizumab trough serum concentrations more than 30 days after the fifth dose will be well above the protective concentration for most infants. Five monthly doses of palivizumab will provide more than 20 weeks of protective serum antibody concentration. In the continental United States, a total of 5 monthly doses for infants and young children with congenital heart disease or chronic lung disease of prematurity or preterm birth before 32 weeks' gestation (31 weeks, 6 days) will provide an optimal balance of benefit and cost, even with variation in season onset and end.
Data from the CDC have identified variations in the onset and offset of the RSV season in Florida that affect the timing of palivizumab administration. Northwest Florida has an onset in mid-November, which is consistent with other areas of the United States. In north central and southwest Florida, the onset of RSV season typically is late September to early October. The RSV season in southeast Florida (Miami-Dade County) typically has its onset in July. Despite varied onsets, the RSV season is of equal duration in the different regions of Florida. Children who receive palivizumab prophylaxis for the entire RSV season should receive palivizumab only during the 5 months following the onset of RSV season specific to their region (maximum of 5 doses).
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